ABSTRACT: Endothelial progenitor cell (EPC) dysfunction contributes to diabetes-induced delay in endothelium repair after vessel injury, prominently associated with diabetic cardiovascular complications such as neointima formation. ATP-binding cassette transporter G1 (ABCG1) promotes cholesterol efflux to HDL, which may favorably affect EPC function. However, whether ABCG1 improves EPC function, especially in diabetes, remains unknown. Here we investigated the role of ABCG1 in EPCs by using Tie2-mediated ABCG1 transgenic (Tie2-ABCG1 Tg ) mice. Mice were injected with streptozotocin to induce diabetes mellitus. As compared with wild-type (WT) mice, in Tie2-ABCG1 Tg mice, diabetes-impaired EPC migration and tube formation were reversed. In vitro gain-of-function and loss-of-function studies further revealed that ABCG1-overexpressing EPCs showed increased migration and tube formation and differentiation via the Lck/Yes-related novel protein tyrosine kinase /Akt/endothelial NO synthase pathway by enhancing cellular cholesterol efflux. Finally, type 1 and type 2 diabetic mouse models with arterial injury were intravenously injected with labeled EPCs from WT or Tie2-ABCG1 Tg mice. Re-endothelialization in diabetic mice was improved to a greater extent by injection of ABCG1-overexpressing than WT EPCs. Our study demonstrated that ABCG1 in EPCs improved repair after vascular injury in diabetes by increasing EPC function such as migration, tube formation and differentiation, and subsequent re-endothelialization. ABCG1 might be a promising therapeutic target for diabetes-associated vascular
About 285 million people worldwide had diabetes mellitus (DM) in 2010, and the number of cases is projected to nearly double by 2030 (1) . Accelerated vascular disease is the leading cause of death and disability with diabetes (2) . Endothelial dysfunction is an early indicator of diabetes-associated vascular disease (3) . Thus, therapeutic interventions to restore dysfunctional endothelium are beneficial for patients with diabetes.
Previous studies have revealed that endothelial progenitor cells (EPCs) play an important role in maintaining endothelial integrity and participate in wound healing, neovascularization in ischemia tissue, and intimal re-endothelialization after vessel wall injury (4, 5) . However, patients with diabetes and animal models have shown reduced numbers of circulating EPCs and impaired EPC function (6, 7) . Furthermore, the re-endothelialization capacity of EPCs was delayed in diabetic mice (3, 8) . Thus, enhancing the number and function of EPCs may be a promising approach for treating diabetic vascular disease.
ATP-binding cassette transporter G1 (ABCG1) is a member of the ABC superfamily. Unlike ABCA1, which mediates cholesterol efflux to lipid-free apolipoproteins, ABCG1 promotes the efflux of intracellular cholesterol to HDL particles (9, 10) . Depending on the cell type, ABCG1 plays a critical role in intracellular sterol homeostasis, inflammation, atherosclerosis, and diabetes (11) . For instance, loss of ABCG1 in pancreatic b-cell impaired glucose tolerance and insulin secretion (12) . b-Cell-specific deletion of ABCA1 and ABCG1 led to b-cell dysfunction, increased adiposity, and systemic inflammation (13) . The roles of ABCG1 in cardiovascular diseases have been studied extensively. Two laboratories found decreased atherosclerotic lesion size in mice with LDL receptor knockout and transplanted with ABCG1 2/2 bone marrow (BM) (14, 15) , whereas another group found a moderate increase (16) . Subsequent studies showed that atherosclerotic lesion development was similar to control mice in ABCG1 2/2 BM recipients, which might be caused by serum cholesterolrelated compensatory up-regulation of ABCA1 (17, 18) . Several recent studies of cultured endothelial cells (ECs) and mice showed that, unlike BM-ABCG1, ABCG1 preserves endothelial function by maintaining endothelial NO synthase (eNOS) activity and reducing the expression of inflammatory factors in ECs (19) . However, little is known about the impact of ABCG1 on EPC function, especially in diabetes-associated vascular diseases.
In the present study, we report that ABCG1, a regulator of cholesterol efflux, improved re-endothelialization in diabetic mice by increasing EPC function. Using gain-of-function and loss-of function assays, we demonstrate that ABCG1 increased eNOS activity through the Lck/Yes-related novel protein tyrosine kinase (Lyn) pathway, thereby enhancing tube formation and migration in EPCs. Our results identify the ABCG1/Lyn/eNOS pathway in EPCs as a potential therapeutic target for diabetic vascular disease.
MATERIALS AND METHODS

Animals
Transgenic mice were generated in a C57BL/6 background driven by the Tie2 promoter. Wild-type (WT) and Tie2-mediated ABCG1 transgenic (Tie2-ABCG1 Tg ) mice were obtained as described (20) . eNOS knock-out (eNOS 2/2 ) mice were kindly provided by Dr. Junjie Xiao (Shanghai University, Shanghai, China). The db/db and db/m mice were purchased from Shanghai Biomodel Organism Center (Shanghai, China). Male mice at age 6-8 wk were used. The investigation conformed to the Guide for the Care and Use of Laboratory Animals [National Institutes of Health (NIH), Bethesda, MD, USA]. All experimental protocols were approved by Institutional Animal Care and Use Committee of Tianjin Medical University.
Reagents VEGF, D-glucose, SU6656, sodium nitroprusside (SNP), cholesterol, and methyl-b-cyclodextrin were purchased from MilliporeSigma (Burlington, MA, USA). Primary antibodies were for GAPDH (Proteintech, Rosemont, IL, USA); ABCG1 (Abcam, Cambridge, MA, USA); and phosphorylated/total Akt, phosphorylated/total eNOS, and phosphorylated/total Lyn (Cell Signaling Technology, Danvers, MA, USA).
Streptozotocin-induced type 1 diabetic mouse models
Mice (6-8 wk old) were injected with streptozotocin (STZ) (MilliporeSigma) (55 mg/kg/d 3 5 d, i.p.). Blood glucose was measured at 1 wk after STZ injection and monitored for another 2 wk. Blood glucose $16.7 mM in mice was considered a successful diabetes model. During the last 2 wk, the mice received recombinant insulin glargine (7 U/kg/d; Lantus, Sanofi Aventis, Germany) or PBS injection subcutaneously twice daily, and wireinduced carotid artery injury was performed. For EPC mobilization assay, mice were injected with recombinant human granulocyte colony-stimulating factor (GRAN; Kyowa Hakko Kirin, Japan) (100 mg/kg per d 3 4 d, s.c.).
Wire-induced carotid artery injury and re-endothelialization assay
Wire-induced carotid denudation was performed as described (21) . Briefly, mice were anesthetized with 1.5% isofluorane, and the left carotid artery was exposed and injured by use of a 0.38-mm guide wire. In some experiments, 1-dioctadecyl-3, 3, 30, 30-tetramethylindocarbocyanine-conjugated acetylated LDL (Dilac-LDL)-labeled EPCs (5 3 10 5 cells) were resuspended in 100 ml PBS and injected via the tail vein 3 h after surgery. Three days after carotid injury, re-endothelialization was assessed by injecting 0.5% Evans Blue Dye (MilliporeSigma) into the tail vein. Mice were then anesthetized with pentobarbital (50 mg/kg, i.p.), and the arteries were harvested. The area resistant to the dye was considered the reendothelialization area. Images were captured with a digital camera and analyzed using ImageJ software (NIH; http://rsb.info.nih.gov/ij/).
Isolation and culture of EPCs
EPCs were isolated from mouse BM as described (22) . Briefly, femurs and tibias were harvested from mice anesthetized with pentobarbital (50 mg/kg, i.p.). EPCs were collected by flushing the femurs and tibias with EBM-2 medium (Lonza, Walkersville, MD, USA) containing 10% fetal bovine serum (FBS). Cells were seeded on dishes coated with type I collagen (MilliporeSigma). After 4 d, nonadherent cells were removed, and the medium was changed every 2 d until cells formed a monolayer of spindleshaped cells. EPCs at passages 2-4 were used for experiments. EPCs were identified by uptake of Dil-ac-LDL and staining with FITC-conjugated ulex europaeus agglutinin I (UEA-1). Additionally, EPCs were characterized by flow cytometry.
Flow cytometry
Cells were incubated for 30 min on ice with the cell-surface marker antibodies FITC-conjugated anti-CD117, anti-CD34, PE-conjugated anti-cluster of differentiation 31 (CD31), anti-kinase insert domain receptor (KDR), and APC-conjugated anti-CD34 or c-kit (BD Biosciences, San Jose, CA, USA). Quantitative flow cytometry involved the use of FACS Calibur (BD Biosciences), and data were analyzed using FlowJo software (BD Biosciences).
Dil-Ac-LDL/lectin staining
Dil-ac-LDL uptake and FITC-UEA-1 binding assay were performed as described (23) . In brief, cells were incubated with 10 mg/ml Dil-ac-LDL (Thermo Fisher Scientific, Waltham, MA, USA) in serum-free medium for 4 h at 37°C, fixed in 4% paraformaldehyde for 10 min, and stained with 10 mg/ml FITC-UEA-1-lectin (MilliporeSigma) at 37°C for 1 h. Cells were examined by confocal microscopy.
Wound healing assay
Monolayer EPCs were wounded with a 200 ml pipette tip, and detached cells were washed with PBS. EPCs were cultured with serum-free EBM-2 medium. Cell migration was recorded at the beginning of wounding and 8 h later. The width of the wound was measured using ImageJ software.
Transwell migration assay
Transwell assay was performed with a Boyden chamber. EPCs (1 3 10 5 ) were suspended in 200 ml serum-free EBM-2 medium and added to the upper chamber. The lower chamber was filled with 600 ml EBM-2 medium supplemented with 5% FBS. In some cases, cells were pretreated with the NO donor SNP (25 mM) for 6 h. After incubation for 4 h, nonmigrating cells were removed with a cotton swab, and migrated cells were stained with DAPI. The stained cells were photographed and counted under a fluorescent microscope.
Tube formation
Growth factor-reduced Matrigel (50 ml/well; BD Biosciences) was added to prechilled 96-well plates, and cells were incubated at 37°C for 45 min. EPCs (1 3 10 4 in 100 ml EBM-2 medium) were seeded on Matrigel. After 4 h, capillary-like structures were imaged and counted.
Cholesterol efflux assay
Cells in 6-well plates were incubated with 50 mg/ml cholesterol in EBM-2 medium containing 0.5% FBS for 24 h. After incubation, cells were washed three times with PBS and equilibrated with EBM-2 medium containing 0.2% bovine serum albumin for 30 min. To initiate cholesterol efflux, cells were incubated with 50 mg/ml recombinant HDL (Yiyuan, Guangzhou, China) for 6 h. Cholesterol content in the medium and cell lysates was measured by mass spectrometry (24) . Cholesterol efflux was determined as the percentage of efflux: (count in medium/total count) 3 100%.
Small interfering RNA transfection and adenovirus infection
EPCs were transfected with specific small interfering RNA (siRNA) or control siRNA using Lipo2000 transfection regent (Thermo Fisher Scientific) following the manufacturer's instructions. siRNA for Abcg1 and Lyn were from Santa Cruz Biotechnology (Dallas, TX, USA). Knockdown efficiency was verified at 48 h posttransfection by real-time PCR and Western blot analysis described as follows. For ABCG1 overexpression, EPCs at 80% confluence were infected with adenovirus (Ad)-human ABCG1 (hABCG1) or Ad-GFP for 48 h at multiplicity of infection 50.
Real-time quantitative PCR
Total RNA was extracted from cells by using Trizol Reagent (Thermo Fisher Scientific). cDNA was obtained from 1 mg RNA by using the Reverse Transcription Reagent Kit, and real-time PCR was performed with the SYBR Green mix (both Thermo Fisher Scientific). Target gene expression was normalized to b-actin level. 
Western blot analysis
EPCs were washed with PBS and harvested in lysis buffer containing protease inhibitors (Roche, Mannheim, Germany) on ice. Protein was separated by SDS-PAGE and electrophoretically transferred to PVDF membranes (MilliporeSigma), which were incubated with primary antibodies overnight at 4°C with gentle shaking and then with horseradish peroxidase-conjugated secondary antibodies for 1 h at room temperature (Proteintech). Bands were visualized with ECL reagents (Thermo Fisher Scientific).
NO production analysis
The content of NO in culture medium was determined by using a Griess Reaction Kit (Beyotime Technology, Beijing, China) according to the manufacturer's instructions.
Statistical analysis
Data are expressed as means 6 SEM. Results were analyzed by an unpaired, 2-tailed Student's t test or 2-way ANOVA with Bonferroni multiple comparison posttest, as appropriate. A value of P , 0.05 was considered statistically significant.
RESULTS
STZ-induced EPC dysfunction was attenuated in ABCG1 transgenic mice
EPCs contribute to maintaining endothelial integrity. To test whether ABCG1 affects EPC function, we first measured the expression of ABCG1 in EPCs of Tie2-ABCG1 Tg mice. BM-derived EPCs (BM-EPCs) were isolated as described (22) and were identified by Dil-ac-LDL and FITC-UEA-1 double staining and flow cytometry (Supplemental Fig. 1A, B) . EPCs from transgenic (Tie2-ABCG1 Tg ) mice showed increased ABCG1 protein levels (Supplemental Fig. 1C ). Then diabetes was induced by STZ injection. Blood glucose level was higher and body weight was lower in diabetic mice than control mice (Supplemental Fig. 2A,  B) . Triglyceride level was increased by STZ regardless of genotype (Supplemental Fig. 2C, D) . Next, we examined whether ABCG1 affects EPC function in WT and diabetic mice. Migration capacity was greater with EPCs from Tie2-ABCG1 Tg than from WT mice, and the diabetes-reduced migration capacity was ameliorated with transgenic mouse EPCs (Fig. 1A) . Furthermore, tube formation ability was better with ABCG1-overexpressed than WT EPCs, and the diabetes-reduced tube formation was reversed (Fig. 1B) .
To further explore the role of ABCG1 in EPCs, the levels of circulating EPCs (CD34
were monitored by flow cytometry. In line with a previous study (6) , the circulating number of EPCs was substantially reduced in diabetic mice, which suggests dysfunction of EPCs in diabetes mellitus; however, the number of circulating EPCs was higher in Tie2-ABCG1 Tg mice under both healthy and diabetic conditions (Fig. 1C) . Next, we explored the effect of ABCG1 on EPC mobilization. Granulocyte colony-stimulating factor-induced EPC mobilization was decreased in STZ-treated mice as compared with controls. In addition, ABCG1 significantly increased EPC mobilization in both control and STZ groups (Supplemental Fig. 2E ). These findings suggest that ABCG1 protects against diabetes-induced EPC dysfunction.
EPCs from ABCG1 transgenic mice showed resistance to high glucose-induced dysfunction Diabetes is characterized by hyperglycemia, which has deleterious effects on EPC function. EPCs under hyperglycemic conditions showed impaired migration and tube formation and decreased NO secretion (25) . To test whether the improved EPC function by ABCG1 in diabetes was due to its protective effects against hyperglycemia-induced EPC dysfunction, we treated EPCs with high glucose (HG) for 48 h to mimic the conditions of diabetic hyperglycemia. Consistent with STZ treatment, with HG treatment, migration of WT EPCs was reduced but to a lesser extent for ABCG1-overexpressed than WT EPCs ( Fig. 2A, B) . Additionally, tube formation ability was significantly impaired by HG treatment in WT EPCs but reversed in ABCG1-overexpressing EPCs (Fig. 2C, D) .
Ad-mediated ABCG1 overexpression promoted EPC migration and tube formation in vitro
To further assess the effects of ABCG1 on EPC function, EPCs were infected with adenovirus to overexpress ABCG1. The cholesterol efflux rate of EPCs was detected, and adenoviral overexpression of ABCG1 promoted cellular cholesterol efflux to HDL (Fig. 3A) . On real-time PCR and flow cytometry of progenitor-specific and endothelialspecific markers, ABCG1 overexpression increased the levels of the endothelial-specific markers CD31 and KDR (also known as VEGF receptor 2) and reduced those of the progenitor-specific markers CD34 and c-kit (Fig. 3B, C) . In addition, as compared with control EPCs, ABCG1-overexpressing EPCs showed increased migratory capacity to a level similar to VEGF stimulation, a positive control (Fig. 3D-G) . Tube formation assays showed similar trends (Fig. 3H, I ). These data indicate that ABCG1 promotes EPC migration and tube formation in vitro.
Knockdown of ABCG1 inhibited EPC migration and tube formation in vitro
To further substantiate the role of ABCG1 in EPC function, we treated EPCs with Abcg1 siRNA to silence Abcg1 (Fig.  4A) . In contrast to ABCG1-overexpressed EPCs, Abcg1 silenced-EPCs showed decreased levels of CD31 and KDR and increased levels of CD34 and c-kit (Fig. 4B, C) . Migration activity was lower in Abcg1-silenced than control EPCs, with VEGF as a positive control (Fig. 4D-G) . Abcg1 silencing significantly decreased capillary-like tube formation of EPCs (Fig. 4H, I ). Moreover, EPC proliferation, migration, and tube formation were greatly increased with VEGF treatment, which was reversed with ABCG1 deficiency (Fig. 4D-I) . Collectively, our results suggest that ABCG1 promotes the differentiation, migration, and angiogenic function of EPCs.
Overexpressing ABCG1 enhanced EPC function via the Lyn/Akt/eNOS pathway We next explored the potential mechanisms linking ABCG1 to enhanced EPC function. Lyn, a member of the Src family of kinases, belongs to nonreceptor tyrosine kinases, consisting of an N-terminal unique region; SH3, SH2, and tyrosine kinase domains; and a short C-terminal tail (26) . The Src family of kinases are involved in many fundamental cellular processes, such as proliferation, differentiation, cell shape, migration, and apoptosis (27) . Lyn kinase, acting as a membrane cholesterol sensor, is activated by decreased membrane cholesterol content (28, 29) . Lyn kinase phosphorylation was notably increased in response to increased ABCG1 expression (Fig. 5A) . To determine whether a change in cellular cholesterol content can recapitulate the effects of ABCG1, we loaded cells with cyclodextrin to remove cellular cholesterol. This removal led to significantly increased Lyn phosphorylation, whereas loading cholesterol with cyclodextrin-cholesterol complexes reduced Lyn phosphorylation (Fig. 5B) .
The Akt/eNOS pathway is essential for EPC differentiation, proliferation, and migration (30). To further assess the possible involvement of Lyn kinase in the regulation of eNOS expression in EPCs, ABCG1-overexpressed EPCs were treated with the Lyn inhibitor SU6656 or Lyn siRNA. Genetic or transient overexpression of ABCG1 activated the Akt/eNOS pathway, as revealed by increased protein levels of phosphorylated Akt and eNOS; SU6656 or Lyn siRNA reversed the activation of this pathway in vitro (Fig.  5C, D) . Furthermore, overexpression of ABCG1 increased eNOS activity, which was inhibited by SU6656 or Lyn siRNA in EPCs (Fig 5E, F) . To confirm the pivotal role of eNOS in EPC function, BM-EPCs were isolated from eNOS knockout mice (eNOS
) or WT mice and transfected with ABCG1 adenovirus. Migratory capacity (Fig. 5G ) and tubule network formation (Fig. 5G) were significantly lower in eNOS 2/2 than WT BM-EPCs. Furthermore, ABCG1 overexpression failed to reverse these inhibitory effects of eNOS deficiency (Fig. 5G) . Next, NO was supplied by the NO donor SNP in ABCG1-knockdown EPCs. SNP reversed the impaired migration and tube formation in EPCs transfected with Abcg1 siRNA (Fig. 5H) . Thus, ABCG1 increases EPC migration and tube-formation capacity via the Lyn/Akt/eNOS pathway.
ABCG1 improved the re-endothelialization ability of EPCs in diabetic mice
ABCG1 has an atheroprotective role and preserves endothelial function. To test whether ABCG1 is involved in postinjury endothelium recovery in diabetic mice, we used wire to injure the carotid arteries of Tie2-ABCG1
Tg diabetic mice. Reendothelialization was measured by en face Evans blue staining of the denuded area at 3 d after injury (Supplemental Fig. 3A) . Re-endothelialization areas were increased by 24% in transgenic (Tie2-ABCG1 Tg ) vs. healthy WT mice (Supplemental Fig. 3B ). However, WT mice showed significantly impaired re-endothelialization under STZ-induced diabetes, which was reversed in ABCG1 transgenic mice.
Because of the broad expression of Tie2 in EPC, other derived cells, such as mature ECs, hematopoietic stem cells, and myeloid cells (31) (32) (33) , may also contribute to the improved re-endothelialization in ABCG1 transgenic mice. To verify the role of ABCG1 in EPCs during reendothelialization in vivo, Dil-ac-LDL-labeled BM-EPCs from Tie2-ABCG1 Tg mice and their WT littermates were injected into tail veins of WT mice with STZ-induced diabetes and carotid artery injury (Fig. 6A) . More Dil-ac-LDL-labeled BM-EPCs from Tie2-ABCG1 Tg than WT mice were incorporated into the injured blood vessel wall (Fig. 6B, C) . Furthermore, the impaired postinjury recovery of endothelium in diabetic mice was reversed with WT-EPC injection but to a greater extent with injection of ABCG1-overexpressed EPCs (Fig. 6D, E) . In addition, insulin ameliorated the re-endothelialization of injured arteries in STZ-treated mice with EPC transplantation, which was comparable between mice with WT and ABCG1-overexpressing EPCs (Fig. 6D, E) .
Next, we tested these findings in db/db mice, a spontaneous type 2 diabetic animal model. Consistent with the (Fig. 6F-J) . Therefore, ABCG1 improved the EPC ability for re-endothelialization to repair the vascular injury in diabetic mice.
DISCUSSION
EPCs were first isolated from human peripheral blood by Asahara et al. (34) . A large body of evidence indicates that EPCs are able to differentiate into mature ECs and contribute to neovascularization in ischemic tissues (34, 35) . The number and function of EPCs may reflect the balance between endothelial integrity and repair (7), which are significantly impaired in diabetes. In this study, we found that: 1) use of a Tie2-specific ABCG1 transgene increased the number of circulating EPCs and improved re-endothelialization after vascular injury in diabetic mice, 2) ABCG1 overexpression in BM-EPCs reversed the HG-impaired EPC migration and tube formation in vitro and re-endothelialization in diabetic mice with vascular injury in vivo, and 3) the preserved EPC function with ABCG1 was via the Lyn/Akt/eNOS pathway. Thus, we provide evidence that ABCG1 promotes the reendothelialization ability of EPCs in diabetic mice by increasing circulating EPC levels and enhancing EPC function.
The content and distribution of cholesterol play essential roles in maintaining cellular membrane physiologic function (36) . An altered cellular cholesterol metabolism network was found associated with type 2 diabetes mellitus and cardiovascular disease by regulating genes related to sterol uptake, synthesis, and efflux. Particularly, genes related to cholesterol efflux (ABCA1 and ABCG1) were down-regulated in circulating monocytes from patients with type 2 diabetes mellitus and cardiovascular disease (37) . These data highlight ABCG1 as a potential therapeutic target in diabetes. Moreover, ABCG1 promotes cholesterol efflux to HDL during reverse cholesterol transport and therefore is considered a critical regulator in various cardiovascular diseases (38) . Increasing HDL levels can improve EPC availability in patients with type 2 diabetes mellitus (39) . HDL treatment could increase the number of circulating EPCs and promote reendothelialization in wound healing (40) . Our study provides evidence that increasing cellular cholesterol efflux likely promotes EPC function. We previously showed that liver X receptor (LXR) activation could restore the HGimpaired adhesion, migration, and tube formation capacity of EPCs via AMPK pathways (41) . ABCG1 is a known transcriptional target of LXR. However, whether with or without Lyn inhibitor pretreatment (SU6656, 10 mg/ml, 2 h) and quantification (C ), and eNOS and Akt phosphorylation levels in EPCs from WT or Tie2-ABCG1 Tg mice transfected with control or Lyn siRNA for 48 h and quantification (D). Tg, Tie2-ABCG1
Tg
. Data are means 6 SEM (n = 5). *P , 0.05, 2-way ANOVA followed by Bonferroni posttest. E, F ) NO production detected in the culture medium of C and D. Data are means 6 SEM (n = 5). *P , 0.05, 2-way ANOVA followed by Bonferroni posttest. G) EPCs from WT and eNOS 2/2 mice were infected with Ad-ABCG1 or Ad-GFP for 48 h. H ) EPCs were transfected with control siRNA or Abcg1 siRNA in the presence of SNP (25 mM) for 6 h. Transwell assay of migrating cells (upper panel) and quantification. Tube formation of EPCs on Matrigel for 4 h (lower panel) and quantification. Cell or tube numbers from 5 random fields were counted in each well. Scale bar, 200 mm. Data are means 6 SEM (n = 5). *P , 0.05, 2-way ANOVA followed by Bonferroni posttest.
ABCG1 IN ENDOTHELIAL PROGENITOR CELLS
LXR-enhanced EPC function depends on ABCG1 warrants further investigation.
Neovascularization of the injured tissue occurs by angiogenesis and vasculogenesis. Angiogenesis is identified by mature EC proliferation and by migration and formation of neovessels around the wound tissues. Vasculogenesis occurs during embryonic life and in postnatal wound healing, whereby EPCs differentiate and process the repair of the vascular network (42) . Recent studies showed that EC-Abca1/g1 deficiency enhanced angiogenesis in aortic Figure 6 . ABCG1 improves the re-endothelialization ability of EPCs in diabetic mice. Male mice (6-8 wk old) were injected with STZ (55 mg/kg/d, i.p.) or vehicle for 5 d. One week later, the mice were injected with insulin or PBS subcutaneously twice daily for 2 wk and then underwent wire-induced carotid artery injury. Dil-ac-LDL-labeled EPCs isolated from WT or Tie2-ABCG1 Tg mice were injected into STZ-induced type 1 diabetic mice after carotid artery injury by wire. A) Experimental protocol. Representative microscopy images of Dil-positive EPCs incorporated into the injured carotid arteries and analysis of the number of EPCs incorporated into the blood vessel wall (per field) in 5 random fields (B, C ). Representative images of reendothelialization of carotid artery by Evans blue staining on d 3 after injury (D, E ). Data are means 6 SEM (n = 5). *P , 0.05, 2-tailed, unpaired Student's t test or 2-way ANOVA followed by Bonferroni posttest. F-J ) Dil-ac-LDL-labeled EPCs isolated from WT or Tie2-ABCG1 Tg mice were injected into db/db mice after carotid artery injury. F ) Experimental protocol. G-J ) Representative microscopy images of Dil-positive EPCs in injured carotid arteries and analysis of the number of EPCs incorporated into the blood vessel wall (per field) in 5 random fields (G, H). Representative images of re-endothelialization of carotid artery by Evans blue staining on d 3 after injury (I, J ). Tg, Tie2-ABCG1 Tg . Data are means 6 SEM (n = 5). *P , 0.05, 2-tailed, unpaired Student's t test or 2-way ANOVA followed by Bonferroni posttest. Scale bars, 50 mm.
rings ex vivo but not during retina vascular developments in vivo (19) . Similarly, a regulator of cholesterol efflux, ApoA-I binding protein, restricted angiogenesis, and deficiency of Abca1 and Abcg1 caused excessive angiogenesis in zebrafish (43 (44) , which suggests a predominant effect of EPCs in our cultured cells.
Lyn kinase is expressed primarily in blood cells and hematopoietic cells, including hematopoietic progenitors, platelets, and erythrocytes (45) . It is palmitoylated and anchored in the plasma membrane and activated via cholesterol depletion by cyclodextrin (29) . A recent study showed that Lyn kinase, as a membrane cholesterol sensor, can be regulated by cholesterol efflux pathways mediated by ABCG4 in megakaryocyte progenitors (28) . With the homology between ABCG1 and ABCG4, we hypothesized that ABCG1 may regulate Lyn kinase via a change in membrane cholesterol content in EPCs. Consistent with previous studies, we found that high levels of ABCG1 and cyclodextrin treatment induced phosphorylation of Lyn kinase in EPCs. However, cholesterol incorporation by the cyclodextrin-cholesterol complex decreased Lyn kinase activity. Furthermore, siRNA knockdown of Lyn protein significantly reduced eNOS and Akt activity. Lyn kinase may act upstream of eNOS protein for regulation.
Terasaka et al. (46) showed that eNOS activity was reduced in aortas of ABCG1 2/2 mice, with no change in eNOS expression or phosphorylation in response to a high-cholesterol diet. However, another group found increased eNOS phosphorylation in aortic ECs from ABCG1 2/2 mice, which might be a counter-regulatory mechanism to the proinflammatory phenotype in these cells (47) . In our study, we observed increased eNOS phosphorylation and activity in cultured EPCs with ABCG1 overexpression. This discrepancy might be due to different characteristics between EPCs and ECs. However, all studies consistently showed that ABCG1 expression is important for protecting against endothelial or EPC dysfunction.
The benefit of EPC transplantation has been observed in clinical studies. EPC injection into ischemic tissues improved tissue perfusion and neovascularization (48) . Several approaches or agents, such as glucagon-like peptide-1 agonist and dipeptidyl peptidase-4 inhibitors, are used to improve EPC number and function in people with diabetes (25) . Our work links the connection between lipid metabolism and vascular pathology. It also demonstrates that ABCG1 improved repair after vascular injury in diabetes by improving EPC function and reendothelialization. We provide further clues that ABCG1 may be a potential target for diabetes-associated vascular diseases. Ai is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
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